| | The right operation for the wrong reason in multi-focal non-small cell lung cancerReceived 30 November 2008; accepted 12 January 2009. Abstract In a sixty-seven year old female smoker, a right lower lobe mass, intimately related to the mediastinum, was detected on computed tomography (CT) scanning. Bronchoscopy confirmed non-small cell lung cancer (NSCLC) and a subsequent integrated 18F-FDG Positron Emission Tomography (PET)/CT scan demonstrated a rim of non-FDG avid tissue between the lung tumour and the mediastinum, and no nodal or distant metastases. The patient was pre-operatively staged as cT3N0M0 and proceeded to exploratory thoracotomy. On histological examination of the resected right lower lobe, multiple deposits of bronchioalveolar cell carcinoma (BAC) were found surrounding a central adenocarcinoma, in addition to a small deposit of adenocarcinoma in a right upper lobe wedge resection sample. Neither the BAC deposits nor the upper lobe disease had been detected on integrated FDG-PET/CT scanning. The final pathological staging of this case (pT4N0M1 (stage IV)) is inconsistent with the improved survival rate of patients with multi-focal intrapulmonary NSCLC confined to the lung over other forms of T4 or M1 disease, particularly when the BAC cell type is involved. This case highlights these major limitations of the current TNM classification and discusses the increased risk of false negative results from integrated FDG-PET/CT scanning in the BAC form of NSCLC. 1. Introduction  The diagnosis and pre-operative assessment of multi-focal intrapulmonary non-small cell lung cancer (NSCLC) poses particular challenges for the lung cancer multi-disciplinary team. Disease confined to the lungs, without nodal or distant metastases can often be treated surgically and a good long-term outcome expected. This is inconsistent with the current TNM classification of NSCLC which classifies multi-focal NSCLC as stage IIIB (T4 disease: deposits in the same lobe as the primary) or stage IV (M1 disease; deposits in a separate lobe), implying a poor long-term survival and discouraging lung resection surgery. The case we report highlights this limitation of the current staging system and discusses particular difficulties encountered in using integrated FDG-PET/CT scanning in the pre-operative assessment of multi-focal intrapulmonary NSCLC, particularly when the bronchioalveolar sub-type is involved as in this case. 2. Case history  A sixty-seven year old female was referred to our unit by the local pancreato-biliary team following the detection of a right lower lobe mass on abdominal computed tomography (CT) scanning performed for another reason. The patient was an ex-smoker, having stopped 4 years ago. When assessed in the respiratory clinic she described a new non-productive cough but no other symptoms. Clinical examination was unremarkable and her WHO performance status was estimated at 0. Review of her recent CT scan demonstrated a 6.5 × 4.1 cm pleural-based mass in the right lower lobe which appeared to encase the medial and inferior aspects of the vascular pedicle of the right hilum and the inferior pulmonary vein. There was no evidence of mediastinal lymphadenopathy but the appearances were highly suspicious of direct mediastinal invasion. Standard fibreoptic bronchoscopy revealed no mucosal abnormality although the medial basal sub-segment of the right lower lobe appeared externally compressed. Cytological samples were taken from this sub-segment by bronchial brush biopsy and saline lavage. Microscopy of the bronchial aspirate demonstrated several groups of large atypical cells with pleomorphic nuclei and distinct cytoplasm consistent with NSCLC. Immunocytochemistry was unhelpful in confirming an origin in lung. Pulmonary function testing revealed mild airflow obstruction (forced expiratory volume in one second 1.55 litres, 65% of predicted) and a corrected diffusion capacity for carbon monoxide that was 67% of predicted. The case was discussed at our multi-disciplinary lung cancer meeting with a view to clarifying the T-staging of the primary tumour and deciding on the patient's suitability for surgical treatment. On review of the CT images it remained impossible to delineate the tumour within the enhancing mass. Since the patient was otherwise an operable candidate an integrated 18F-FDG Positron Emission Tomography (PET)/CT scan was arranged to help clarify the T-staging and screen for mediastinal nodal disease or distant metastases (see Fig. 1). This revealed intense FDG uptake (SUV 12.0 g/ml) within the inferolateral aspect of the soft tissue mass, presumed to represent the viable tumour. However, in the medial aspect of the mass, adjacent to the left atrium there was a rim of soft tissue that showed no significant FDG activity. This was presumed to be collapsed lung lying adjacent to the tumour and separating it from the mediastinum. There was no evidence of nodal disease or distant metastases. Therefore, the patient was pre-operatively staged as cT3N0M0 and proceeded to exploratory thoracotomy. At thoracotomy a large tumour was found in the right lower lobe. In keeping with the results of integrated FDG-PET/CT scanning, there was no evidence of mediastinal invasion. However, the tumour was adherent across the major fissure into the upper lobe and a wedge resection of the adjacent area of the upper lobe was performed in addition to a right middle and lower bilobectomy. The patient made an uneventful post-operative recovery and histology from the resected lung tissue revealed a moderately differentiated adenocarcinoma located centrally within the visible tumour mass (see Fig. 2(a)). The periphery of the mass was occupied by bronchioalveolar cell carcinoma (BAC) of mucinous type and there were several other small foci of BAC some distance from the primary tumour mass within the right lower lobe (see Fig. 2(b)). The right upper lobe wedge resection sample showed moderately differentiated adenocarcinoma with clear resection margins and the right middle lobe was free of tumour. Neither vascular nor lymphatic invasion were identified and all 17 of the lymph-nodes sampled (right pulmonary artery, hilar and peribronchial nodes) were negative. Although the surgeon was confident that the entire tumour had been removed, she will be considered for adjuvant therapy given her final pathological staging of pT4N0M1 multi-focal adenocarcinoma/BAC. 3. Discussion  Following FDG-PET/CT scanning this patient was pre-operatively staged as cT3N0M0 and proceeded to exploratory thoracotomy with a view to potentially curative surgical resection. Although there was no evidence of direct mediastinal invasion at thoracotomy, as shown by the pre-operative FDG-PET/CT scan, there were small multi-focal deposits of BAC surrounding the central tumour mass in the right lower lobe and a deposit of adenocarcinoma in the right upper lobe. This case highlights the limitations of the current TNM classification of NSCLC when applied to patients with multi-focal intrapulmonary NSCLC without nodal or distant metastases. It also emphasises the relative strengths and weakness of integrated FDG-PET/CT scanning, which is becoming an increasingly well established and widely available part of pre-operative lung cancer assessment. 3.1. TNM classification in multi-focal NSCLC According to the current TNM classification of NSCLC, pulmonary metastases (PM) within the same lobe (described as PM1) constitute T4 disease (stage IIIB) while PM within a separate lobe (PM2) constitute metastatic (stage IV) disease. The patient reported was therefore staged as pT4N0M1. The appropriateness of this staging approach in this clinical scenario has been debated recently because most investigators, outside Japan, have demonstrated greatly improved long-term survival of patients with isolated node-negative PM1 and PM2 disease treated surgically compared to patients with any other form of T4 and M1 disease.1, 2, 3 This contrast has prompted calls for the down-staging of PM1 (currently T4) lesions to T3 disease and PM2 (currently M1) lesions to T4 disease in the TNM re-classification of NSCLC due in 2009.3 Derivation of useful prognostic information from the current TNM classification becomes even more difficult in multi-focal BAC. In this context, complete surgical resection is often successful in patients without nodal or extra-pulmonary disease and the current NSCLC system does not predict survival. This is illustrated in one recent surgical series in which a 64% 5-year survival rate was seen following complete resection, irrespective of whether the disease was bilateral,4 in which case an M1 staging label would be applied based on the current TNM system. This label is clearly incongruent with a long-term survival rate following surgery that approaches that seen in localised stage 1 or 2 NSCLC of other cell types. 3.2. Integrated FDG-PET/CT scanning Our case also highlights the relative strengths and weakness of integrated FDG-PET/CT scanning. It is widely known that the low spatial resolution of FDG-PET imaging makes the detection of small deposits of lung cancer (<9 mm in diameter) difficult. Our case illustrates the well known belief that integrated FDG-PET/CT scanning provides little additional information over conventional CT in detecting small metastases. It is perhaps less well known that PET sensitivity is also affected by tumour type. Studies in which this modality has been used to assess suspicious intrapulmonary abnormalities have reported a greater risk of false negative results with adenocarcinoma or BAC, both of which were found in the false negative areas of lung in the patient described. In one study reported recently, 65% of the 20 false negative results reported in a population of nearly 4000 patients (an overall false negative rate of only 0.5%) were attributed to these cell types.5 The particularly high false negative rate of BAC is probably due to the lower turnover of glucose in this more biologically indolent form of lung cancer.6 In the case reported, we interpreted the rim of non-FDG avid tissue surrounding the primary tumour mass on the pre-operative integrated FDG-PET/CT scan as collapsed lung, separating the tumour from the mediastinum and excluding T4 disease. This conclusion was based on evidence extrapolated from recent reports of the successful use of integrated FDG-PET/CT scanning as means of defining tumour volume for radiotherapy treatment planning in NSCLC.7, 8 In retrospect, this area may have represented a truly false negative result caused by the rim of BAC found around the central tumour mass on histological examination. In conclusion, therefore, the patient reported appears to have received the right operation for multi-focal NSCLC, albeit for the wrong reasons based on pre-operative staging investigations. This case highlights the combined difficulties in applying the current TNM classification and the results of integrated FDG-PET/CT imaging in patients with multi-focal intrapulmonary NSCLC without nodal or distant metastases, especially when the BAC sub-type is involved. Conflicts of interest Statement  The authors have no statements of interest to declare. References  1. 1Battafarano RJ, Meyers BF, Guthrie TJ, Cooper JD, Patterson GA. Surgical resection of multifocal non-small cell lung cancer is associated with prolonged survival. Ann Thorac Surg. 2002 Oct;74(4):988–993. MEDLINE |
CrossRef
2. 2Bryant AS, Pereira SJ, Miller DL, Cerfolio RJ. Satellite pulmonary nodule in the same lobe (T4N0) should not be staged as IIIB non-small cell lung cancer. Ann Thorac Surg. 2006 Nov;82(5):1808–1813.
CrossRef
3. 3Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, Travis WD, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007 Jul;2(7):593–602. 4. 4Roberts PF, Straznicka M, Lara PN, Lau DH, Follette DM, Gandara DR, et al. Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved. J Thorac Cardiovasc Surg. 2003;126(5):1597. Abstract | Full Text |
Full-Text PDF (94 KB)
|
CrossRef
5. 5Cheran SK, Nielsen ND, Patz EF. False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications. Am J Roentgenol. May 1, 2004;182(5):1129–1132. 6. 6Kim BT, Kim Y, Lee KS, Yoon SB, Cheon EM, Kwon OJ, et al. Localized form of bronchioloalveolar carcinoma: FDG PET findings. Am J Roentgenol. April 1, 1998;170(4):935–939. 7. 7Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):78–86. Abstract | Full Text |
Full-Text PDF (364 KB)
|
CrossRef
8. 8Jarritt PH, Carson KJ, Hounsell AR, Visvikis D. The role of PET/CT scanning in radiotherapy planning. Br J Radiol. September 1, 2006;79(Special_Issue_1):S27–S35.
CrossRef
a Respiratory Department, Glasgow Royal Infirmary, UK b Radiology Department, Glasgow Royal Infirmary, UK c Department of Cardiothoracic Surgery, Glasgow Royal Infirmary, UK d Pathology Department, Glasgow Royal Infirmary, UK Corresponding author at: Respiratory Department, Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 0YN, UK. Tel.: +44 141 211 3000; fax: +44 141 211 6334.
PII: S1755-0017(09)00016-5 doi:10.1016/j.rmedc.2009.01.014 © 2009 Elsevier Ltd. All rights reserved. | |
|